Literature DB >> 1450492

Therapeutic trials on progressive muscular dystrophy.

E Satoyoshi1.   

Abstract

The special medical care in the National Sanatorium prolonged the life span of the patients with progressive muscular dystrophy from 15.8 years to 20.4 years over the last 20 years. Various new drug trials for muscular dystrophy have been implemented in the last 12 years in Japan. Bestatin and Loxistatin, protease inhibitors, showed definite improvement on dystrophic mice or hamsters, animal models of muscular dystrophy. However clinical application of these drugs failed to prove the effects on patients with Duchenne muscular dystrophy. The difficulty of clinical evaluation and judgement of effects in progressive neurological diseases is discussed.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1450492     DOI： 10.2169/internalmedicine.31.841

Source DB:  PubMed          Journal:  Intern Med        ISSN： 0918-2918            Impact factor:   1.271


  17 in total

1.  Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation.

Authors:  K Doh-Ura; T Iwaki; B Caughey
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors.

Authors:  Isaac T Schiefer; Subhasish Tapadar; Vladislav Litosh; Marton Siklos; Rob Scism; Gihani T Wijewickrama; Esala P Chandrasena; Vaishali Sinha; Ehsan Tavassoli; Michael Brunsteiner; Mauro Fa'; Ottavio Arancio; Pavel Petukhov; Gregory R J Thatcher
Journal:  J Med Chem       Date:  2013-07-22       Impact factor: 7.446

Review 3.  Calpain research for drug discovery: challenges and potential.

Authors:  Yasuko Ono; Takaomi C Saido; Hiroyuki Sorimachi
Journal:  Nat Rev Drug Discov       Date:  2016-11-11       Impact factor: 84.694

4.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Fibrillar α-synuclein toxicity depends on functional lysosomes.

Authors:  Stephanie J Guiney; Paul A Adlard; Peng Lei; Celeste H Mawal; Ashley I Bush; David I Finkelstein; Scott Ayton
Journal:  J Biol Chem       Date:  2020-10-07       Impact factor: 5.157

6.  Cathepsin S Contributes to the Pathogenesis of Muscular Dystrophy in Mice.

Authors:  Andoria Tjondrokoesoemo; Tobias G Schips; Michelle A Sargent; Davy Vanhoutte; Onur Kanisicak; Vikram Prasad; Suh-Chin J Lin; Marjorie Maillet; Jeffery D Molkentin
Journal:  J Biol Chem       Date:  2016-03-10       Impact factor: 5.157

7.  Cysteine Cathepsin Inhibitors as Anti-Ebola Agents.

Authors:  Wouter A van der Linden; Christopher J Schulze; Andrew S Herbert; Tyler B Krause; Ariel A Wirchnianski; John M Dye; Kartik Chandran; Matthew Bogyo
Journal:  ACS Infect Dis       Date:  2016-01-20       Impact factor: 5.084

8.  Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.

Authors:  Gregory Hook; Jin Yu; Thomas Toneff; Mark Kindy; Vivian Hook
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

9.  The cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for traumatic brain injury.

Authors:  Gregory R Hook; Jin Yu; Nancy Sipes; Michael D Pierschbacher; Vivian Hook; Mark S Kindy
Journal:  J Neurotrauma       Date:  2014-02-06       Impact factor: 5.269

10.  Fibrillar α-synuclein toxicity depends on functional lysosomes.

Authors:  Stephanie J Guiney; Paul A Adlard; Peng Lei; Celeste H Mawal; Ashley I Bush; David I Finkelstein; Scott Ayton
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.